EUCTR2012-002933-12-GB进行中（未招募）1 期
A Phase II pilot study to explore treatment with Sodium Valproate in Adults with McArdle Disease (Glycogen Storage Disorder Type V, GSDV) - Sodium Valproate for GSDV Version 1.0 13th January 2014
niversity College London,0 个研究点目标入组 8 人开始时间: 2014年4月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male and infertile/ post menopausal female subjects diagnosed with GSDV and over 18 years of age.
- •Diagnosis will be confirmed by either muscle biopsy showing subsarcolemmal blebs of glycogen with complete absence of skeletal muscle glycogen phosphorylase and/or DNA studies showing pathogenic homozygous or compound heterozygous mutations or deletion in the muscle phosphorylase gene (PYGM).
- •2. Prior to recruitment all subjects will have been shown to have normal serum carnitine level and acylcarnitine blood profile.
- •3. Patients with mild elevation in bilirubin caused by Gilbert's syndrome will be included following assessment and according to the clinical judgment of the investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Children under the age of 18 years
- •2. People older than 64 years
- •3. Females of child bearing potential
- •4. Patients with Diabetes
- •5. Inflammatory disorders especially Systemic lupus erythematosis.
- •6. A previous history of sensitivity/allergy to sodium valproate and its excipients
- •7. Patients treated with sodium valproate for epilepsy or a psychiatric disorder within the last 12 months prior to recruitment
- •8. Patients with pre-existenig liver disease or a family history of severe liver disease affecting a first degree relative. Liver disease will be defined by abnormal liver biopsy. Patients with GSDV will have raised serum transaminases that originate from muscle but which may cause abnormal liver function tests measured in serum, this will not be a reason for exclusion.
- •9. Patients prescribed other anti-convulsant medication or any other medication known to interact with sodium valproate.
- •10. Patients who are sensitive to local anaesthetics that would prevent a muscle biopsy.
- •11. Subjects with any co-morbid illness or disability which would prevent an exercise assessment such as severe unstable/untreated ischaemic heart disease, lower limb disability such as severe muscle weakness with muscle strength assessed as worse than MRC scale 3 in any pelvic girdle muscle.
- •12. Inability to exercise due to a lower limb fracture until there is a complete recovery of the injury.
- •13. Patients known to have porphyria or an affected first degree relative affected with porphyria
- •14. Patients known to have mitochondrial disease or where there is a first degree relative with mitochondrial disease
- •15. Patients with an abnormal acyl carnitine profile or low serum carnitine levels
- •16. Male participants unwilling to use contraception
研究者
相似试验
招募中
1 期
MK-4280 and Pembrolizumab in Hematologic MalignanciesCTIS2023-503587-17-00Merck Sharp & Dohme LLC140
进行中（未招募）
1 期
MK-4280 and Pembrolizumab in Hematologic MalignanciesHematologic malignanciesMedDRA version: 21.1Level: LLTClassification code 10025315Term: Lymphoma malignantSystem Organ Class: 100000004864EUCTR2018-001461-16-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.84
进行中（未招募）
1 期
MK-4280 and Pembrolizumab in Hematologic MalignanciesHematologic malignanciesMedDRA version: 21.1Level: LLTClassification code 10025315Term: Lymphoma malignantSystem Organ Class: 100000004864EUCTR2018-001461-16-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.84
已完成
2 期
Investigator-initiated Phase 2 clinical study of S-005151 in patients with osteoarthritis of the kneeOsteoarthritis of the kneeJPRN-jRCT2021200034Ishibashi Yasuyuki20
已完成
2 期
effect of Sovodak in patients with hepatitis C and HIV-1Condition 1: Hepatitis C and HIV. Condition 2: Human immunodeficiency virus.Acute hepatitis CHuman immunodeficiency virus [HIV] diseaseIRCT20180924041107N1Tabriz University of Medical Sciences22